College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 313200, China; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Crit Rev Oncol Hematol. 2024 Oct;202:104470. doi: 10.1016/j.critrevonc.2024.104470. Epub 2024 Aug 6.
The liver is a frequent site of metastasis in advanced gastric cancer (GC). Despite significant advancements in diagnostic and therapeutic techniques, the overall survival rate for patients afflicted with gastric cancer liver metastasis (GCLM) remains dismally low. Precision oncology has made significant progress in identifying therapeutic targets and enhancing our understanding of metastasis mechanisms through genome sequencing and molecular characterization. Therefore, it is crucial to have a comprehensive understanding of the various molecular processes involved in GCLM and the fundamental principles of systemic therapy to develop new treatment approaches. This paper aims to review recent findings on the diagnosis, potential biomarkers, and therapies targeting the multiple molecular processes of GCLM, with the goal of improving treatment strategies for patients with GCLM.
肝脏是晚期胃癌(GC)转移的常见部位。尽管在诊断和治疗技术方面取得了重大进展,但患有胃癌肝转移(GCLM)的患者的总体生存率仍然很低。通过基因组测序和分子特征分析,精准肿瘤学在确定治疗靶点和增强我们对转移机制的理解方面取得了重大进展。因此,全面了解 GCLM 涉及的各种分子过程以及系统治疗的基本原则对于开发新的治疗方法至关重要。本文旨在综述 GCLM 多个分子过程的诊断、潜在生物标志物和治疗靶点的最新研究发现,以期改善 GCLM 患者的治疗策略。